Loading…
Natco Pharma (NATCOPHARM)₹804.35−0.09%Pharmaceuticals
At the end of the Jun 2026 quarter, Natco Pharma's shareholders were: promoters 49.45%, FIIs 16.97%, DIIs 5.62%, public 27.96%. Promoter holding is unchanged on the quarter. FII holding is up 1.47 percentage points from 15.50% a year earlier. It had 4,03,112 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 49.75% | 49.75% | 49.75% | 49.75% | 49.66% | 49.66% | 49.60% | 49.60% | 49.52% | 49.52% | 49.45% | 49.45% |
| FIIs | 12.80% | 13.70% | 16.12% | 17.43% | 17.49% | 17.92% | 17.47% | 15.50% | 14.07% | 15.14% | 17.35% | 16.97% |
| DIIs | 14.00% | 11.25% | 9.68% | 7.85% | 6.74% | 5.58% | 5.63% | 5.80% | 5.86% | 5.38% | 5.45% | 5.62% |
| Public | 23.45% | 25.30% | 24.45% | 24.97% | 26.11% | 26.84% | 27.30% | 29.10% | 30.55% | 29.96% | 27.75% | 27.96% |
| Number of shareholders | 1,63,731 | 2,07,543 | 2,28,437 | 2,51,451 | 3,02,904 | 3,45,286 | 4,05,168 | 4,29,377 | 4,19,643 | 4,24,110 | 4,10,915 | 4,03,112 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| V C Nannapaneni | Promoter | 15.63% | 0.00 |
| Time Cap Pharma Labs Private Limited | Promoter | 9.65% | 0.00 |
| Venkata Satya Swathi Kantamani | Promoter | 8.91% | 0.00 |
| Natsoft Information Systems Pvt Ltd | Promoter | 8.78% | 0.00 |
| Belgrave Investment Fund | FII | 2.32% | 0.00 |
| Vistra ITCL India Limited A/c Neelima Nannapaneni Trust | Promoter | 2.29% | 0.00 |
| Life Insurance Corporation Of India | DII | 2.26% | −0.05 |
| Durga Devi Nannapaneni | Promoter | 1.97% | 0.00 |
| Akash Bhanshali | Public | 1.00% | 0.00 |
| Rajeev Nannapaneni | Promoter | 0.59% | 0.00 |
| Vistra ITCL India Limited A/c Durgadevi Family Trust | Promoter | 0.33% | 0.00 |
| T Anila | Promoter | 0.32% | 0.00 |
| T Ananda Babu | Promoter | 0.23% | 0.00 |
| Vidyadhari Tummala | Promoter | 0.21% | 0.00 |
| Satya Vani Nannapaneni | Promoter | 0.19% | 0.00 |
| Neelima Sita Nannapaneni | Promoter | 0.10% | 0.00 |
| Sanjay Nannapaneni | Promoter | 0.09% | 0.00 |
| Ndl Infratech Private Limited | Promoter | 0.05% | 0.00 |
| Tummala Jansi | Promoter | 0.04% | 0.00 |
| Kantamani Ratna Kumar | Promoter | 0.03% | 0.00 |
| Devendranth Alapati | Promoter | 0.01% | 0.00 |
| Natco Aqua Limited | Promoter | 0.01% | 0.00 |
Promoters held 49.45% of Natco Pharma at the end of the Jun 2026 quarter, down 0.15 percentage points from 49.60% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 16.97% (down 0.38 percentage points from 17.35% a quarter earlier) and domestic institutions (DIIs) held 5.62% (up 0.17 percentage points from 5.45% a quarter earlier).
Natco Pharma had 4,03,112 shareholders at the end of the Jun 2026 quarter, against 4,29,377 a year earlier.
Belgrave Investment Fund (FII) held 2.32% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.